Skip to content
Evigrade
CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative

Updated · Methodology

Mechanism

Both drugs are monoamine oxidase (MAO) inhibitors. Tranylcypromine irreversibly and non-selectively inhibits MAO types A and B, the enzyme that breaks down serotonin, noradrenaline and dopamine inside cells and neurons (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Phenelzine is also an MAO inhibitor (phenelzine label, US Food and Drug Administration, FDA, Precautions). According to the US tranylcypromine label, adding another MAO inhibitor further increases MAO inhibition and the risk of adverse reactions, serotonin syndrome and hypertensive reactions (tranylcypromine FDA label, section 7.1). Tranylcypromine and its metabolites are eliminated within 24 hours, but full MAO activity returns only after 3–5 days (tranylcypromine SmPC, AEMPS, section 5.1). According to the US label, MAO inhibition may persist for up to 10 days after stopping (tranylcypromine FDA label, section 5.9).

Symptoms

The US phenelzine label prohibits combining phenelzine with other monoamine oxidase (MAO) inhibitors, including tranylcypromine, because hypertensive crises, seizures, fever, marked sweating, excitation, delirium, tremor, coma and circulatory collapse may occur (phenelzine label, US Food and Drug Administration, FDA, Contraindications). According to the Spanish tranylcypromine summary of product characteristics (SmPC), other MAO inhibitors carry a risk of symptoms similar to serotonin syndrome (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). A hypertensive crisis presents with an occipital headache that may spread to the forehead, palpitations, neck stiffness or soreness, nausea or vomiting, sweating, dilated pupils and sensitivity to light. The heart rate may be fast or slow, sometimes with constricting chest pain. Intracranial bleeding, sometimes fatal, has been reported with the rise in blood pressure (tranylcypromine FDA label, section 5.2). Serotonin syndrome presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, sweating, high temperature), tremor, rigidity, myoclonus, overactive reflexes, seizures, nausea, vomiting and diarrhoea, and it can be fatal (tranylcypromine FDA label, section 5.3).

Management

The combination is contraindicated. The Spanish tranylcypromine summary of product characteristics (SmPC) prohibits other monoamine oxidase (MAO) inhibitors (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The US phenelzine label lists tranylcypromine among the MAO inhibitors that must not be given together with phenelzine or in rapid succession (phenelzine label, US Food and Drug Administration, FDA, Contraindications). The US tranylcypromine label also contraindicates other MAO inhibitors (tranylcypromine FDA label, sections 4.1 and 7.1). Phenelzine is not authorised in Spain (AEMPS medicines register), so information on it comes from the US label. Start tranylcypromine no earlier than two weeks after stopping phenelzine, and start phenelzine no earlier than 14 days after stopping tranylcypromine (tranylcypromine SmPC, AEMPS, section 4.2; FDA phenelzine label, Contraindications). Exclude foods high in tyramine from one day before tranylcypromine is started, throughout treatment and for 14 days after it is stopped (tranylcypromine SmPC, AEMPS, sections 4.4 and 4.5). With phenelzine, avoid them during treatment and for two weeks after stopping (FDA phenelzine label, Warnings). Measure blood pressure before starting tranylcypromine and monitor it closely during treatment (tranylcypromine FDA label, sections 2.4 and 5.2). With phenelzine, check blood pressure often and stop phenelzine at once if palpitations or frequent headaches appear (FDA phenelzine label, Warnings). At the first signs of a hypertensive crisis, interrupt treatment, assess the patient at once and stop any drug that may have caused it. If blood pressure is severely raised (for example, above 180/120 mm Hg) with signs of organ damage, lower it immediately (tranylcypromine FDA label, section 5.2). The US phenelzine label recommends phentolamine for this purpose (a reported dose of 5 mg intravenously), given slowly to avoid an excessive fall in blood pressure. Manage fever with external cooling (FDA phenelzine label, Warnings).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Phenelzine

Other interactions with Tranylcypromine